GuidelineInvestigative and clinical urology2016
Korean clinical practice guideline for benign prostatic hyperplasia.
Guideline in Investigative and clinical urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Korean clinical practice guideline for benign prostatic hyperplasia.Investigative and clinical urology · 2016Guideline
- SHProInvestigative and clinical urology · 2025Trial
- Efficacy and safety of low power holmium laser enucleation of the prostate: A prospective short- and medium-term single-blind randomized trial.Investigative and clinical urology · 2023Trial
- Trial
- Trial
- Influence of solifenacin on the improvement of storage symptoms in the early period after photoselective vaporization of the prostate.Investigative and clinical urology · 2019Trial
- Green Light photoselective vaporization of the prostate: a safe and effective treatment for elderly high-risk benign prostate hyperplasia patients with gland over 80 ml.Lasers in medical science · 2018Trial
- Comparative Trends in the Treatment of Male Lower Urinary Tract Symptoms in South Korea and the United States of America (USA) Based on Korean National Health Insurance Data.The world journal of men's health · 2026Article
- Prescription Trends of Initial Pharmacotherapy for Benign Prostatic Hyperplasia Among Treatment-Naïve Patients in South Korea: A Retrospective Analysis.Lower urinary tract symptoms · 2025Article
- Article
- Feasibility study on a new enhanced device for patients with intermittent catheterization (LUJA).Journal of preventive medicine and hygiene · 2023Article
- Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study.Prostate international · 2023Article
- Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement.The Cochrane database of systematic reviews · 2023Review
- Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.JAMA network open · 2023Article
- Robotic-assisted simple prostatectomy versus holmium laser enucleation of the prostate for large benign prostatic hyperplasia: A single-center preliminary study in Korea.Prostate international · 2022Article
- Article
- Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers.Translational and clinical pharmacology · 2020Article
- Observational
- Expression of bladder αInvestigative and clinical urology · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2014, the Korean Urological Association organized the Benign Prostatic Hyperplasia Guideline Developing Committee composed of experts in the field of benign prostatic hyperplasia (BPH) with the participation of the Korean Academy of Family Medicine and the Korean Continence Society to develop a Korean clinical practice guideline for BPH. The purpose of this clinical practice guideline is to provide current and comprehensive recommendations for the evaluation and treatment of BPH. The committee developed the guideline mainly by adapting existing guidelines and partially by using the de novo method. A comprehensive literature review was carried out primarily from 2009 to 2013 by using medical search engines including data from Korea. Based on the published evidence, recommendations were synthesized, and the level of evidence of the recommendations was determined by using methods adapted from the 2011 Oxford Centre for Evidence-Based Medicine. Meta-analysis was done for one key question and four recommendations. A draft guideline was reviewed by expert peer reviewers and discussed at an expert consensus meeting until final agreement was achieved. This evidence-based guideline for BPH provides recommendations to primary practitioners and urologists for the diagnosis and treatment of BPH in men older than 40 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.